Bionano Genomics vs Seer
Bionano Genomics is the larger business, with $28.5m of revenue in fiscal 2025 against $16.6m for Seer (1.7 times as much). Seer grew faster (17.0% against -7.4%). Bionano Genomics kept more of each dollar of sales as profit: a net margin of -92.6% against -444.0%. Bionano Genomics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Bionano GenomicsBNGO, 2025 | SeerSEER, 2025 |
|---|---|---|
| Revenue | $28.5m | $16.6m |
| Revenue growth | -7.4% | 17.0% |
| Net income | −$26.4m | −$73.6m |
| Operating margin | -116.9% | -470.5% |
| Net margin | -92.6% | -444.0% |
| Return on equity | -66.2% | -25.1% |
| Free cash flow | −$16.3m | −$46.2m |
| Cash | $3.0m | $47.3m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 97 | — |
| Market value | $14.1m | $94.7m |
| Price vs our value range | — | — |
| Moat score | 11 (Weak) | 22 (Weak) |
| Insider trades, 12 months | 2 buys, 0 sales | 0 buys, 7 sales |